Supplementary material to article by M. E. Kubin et al. "Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory $TNF\alpha - IL-23 - IL-17 Axis$ "



Fig. S2. The numbers of Th17 and Th22 cells in peripheral blood mononuclear cell (PBMC) samples analysed by flow cytometry. As representative samples, PBMC samples from a psoriatic patient (a) before and (b) after one week of betamethasone monotherapy and samples from another psoriatic patient (c) before and (d) after 1 week of calcipotriol/betamethasone combination therapy are shown. CD4⁺ T cells were selected from PBMC samples (*first column*). Memory CD4⁺ T cells were identified as CD4⁺, CD45RA- T cells (*second column*). Th17 memory cells were identified from memory CD4⁺ T cells as CD4⁺, CCA574, CCR6⁺ cells (*third column*). Th22 memory cells were identified from Th17 memory cells as CD4⁺, CD45RA-, CXCR3⁻, CCR6⁺, CCH10⁺ cells and (*fourth column*) and skin-homing Th17 cells as CD4⁺, CD45RA-, CXCR3⁻, CCR6⁺, CLA⁺ cells (*fifth column*). Both topical therapies reduced the numbers of Th22 cells (*fourth column*: combination therapy from 10.6% to 7.45% and monotherapy from 9.52% to 4.64%) and skin homing CLA⁺ Th17 cells (*fifth column*: combination therapy from 12.6% to 6.91%).

ActaDV

ActaDV Acta Dermato-Venereologica

Acta Derm Venereol 2017